Blow For Janssen As England's NICE Rejects Depression Spray Spravato

Draft Guidance Out For Consultation Until 18 February

Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.

Blurred_Woman_Depression — NICE says Spravato should not be used on the NHS for patients with depression • Source: Shutterstock

NICE, the health technology appraisal body for England, has issued preliminary guidance rejecting Janssen's nasal spray Spravato (esketamine) for patients with treatment-resistant depression (TRD).

Uncertainties over clinical and cost effectiveness have resulted in NICE recommending against Spravato’s use on the National Health Service, according...